• Subscribe
  • Advertise
  • About us
  • Follow
  • Follow
  • Follow
  • Follow
Pharmafile Logo
  • Magazine
    • PharmaTimes Magazine Archive
  • Web Exclusives
  • News
  • Competitions
  • Appointments
  • Business Insights
  • Webinars
  • Thought Leadership

Contact

News alerts

This field is required.

Latest content

  • Heparegenix completes first darizmetinib treatment in phase 1b
  • Ethiopia, Norway and UK boost global epidemic preparedness
  • AstronauTx receives funding for Parkinson’s sleep research
  • Roche welcomes MHRA approval of Gazyvaro
  • Grünenthal acquires cancer medicine Stivarga

Contact details

PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN

E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999

Get the latest pharma news delivered to your inbox

A valid email address is required.

Download our apps

Go to the App Store or Google Play and search for ‘PharmaTimes’ to download our free app.

Content

News
Magazine
Advertise
Contact
Competitions

Connect

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Legal

Privacy Policy
Terms and Conditions
Editorial policy
Cookies
RSS – feed subscriptions
© Copyright PharmaTimes Media Limited 2026